Company Overview:

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

[stock_market_chart symbol=”MYM.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$0.12
Market Capitalization (in Millions)$15.09
Last Quarter (Share Data)2/28/2019
Shares Outstanding (in Millions)125.72
Options (in Millions)9.11
Warrants (in Millions)14.09
Fully Diluted (in Millions)148.91
<th<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td
<!DOCTYPEhtml><metaname="google"content="notranslate"><metaname="viewport"content="target-densitydpi=device-dpi,user-scalable=1,minimum-scale=1,maximum-scale=2.5,initial-scale=1,width=device-width"><metahttp-equiv="X-UA-Compatible"content="IE=edge;"><metaname="referrer"content="origin">MYM</td><td class="column-11">Nutraceuticals</td><td class="column-12">-</td><td class="column-13">Google</td><td class="column-14">Drive<linkrel="shortcuticon"href="//ssl.gstatic.com/docs/spreadsheets/favicon3.ico"><linkhref='/static/spreadsheets2/client/css/2968578022-waffle_k_ltr.css'type='text/css'rel='stylesheet'nonce="Fw9E7jRvoxHul7G8hNScZg"><styletype="text/css"nonce="Fw9E7jRvoxHul7G8hNScZg">
html{overflow:visible;}
#sheets-viewport{overflow:auto;}
#sheets-viewport.widget-viewport{overflow:hidden;}
.grid-container{overflow:visible;background:white;}
.grid-table-container{overflow:visible;}
#top-bar{
margin:0;
overflow:hidden;
}
#top-bar{
border-bottom:1pxsolid#ccc;
padding:6px6px0;
}
#doc-title{padding-bottom:5px;}
#doc-title.name{font-size:15px;}
#sheet-menu{
font-size:13px;
margin:6px00;
padding:005px;
}
#sheet-menuli{
display:inline;
list-style-type:none;
margin:0;
padding:5px8px;
}
#sheet-menuli.active{
background-color:#fff;
font-weight:bold;
border:1pxsolid#999;
}
#top-bar#sheet-menuli.active{
border-bottom:0;
}
#sheet-menua,#sheet-menua:visited{color:#07c;}
#footer{
background:#f0f0f0;
border-top:1px#cccsolid;
border-bottom:1px#cccsolid;
font-size:13;
padding:10px10px;
}
.dash{
padding:06px;
}
.ritz.wafflea{color:inherit;}.ritz.waffle.s1{background-color:#ffffff;text-align:center;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}.ritz.waffle.s0{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">
varactiveSheetId;
functionswitchToSheet(id){
if(document.getElementById('sheet-menu')){
document.getElementById('sheet-button-'+activeSheetId)
.className='';
document.getElementById('sheet-button-'+id).className='active';
}
document.getElementById(activeSheetId).style.display='none';
document.getElementById(id).style.display='';
activeSheetId=id;
//posObjs()isdefinedinembeddedObjectJs(seeEmbeddedObjectHtmlBuilder.java)
posObjs();
returnfalse;
}
functioninit(){
varoptPageSwitcher;
functionresize(){
varoptMobileWebHeader=document.getElementById('docs-ml-header-id');
varoptTopBar=document.getElementById('top-bar');
varoptFooter=document.getElementById('footer');
varsheetsViewport=document.getElementById('sheets-viewport');
if(optMobileWebHeader){
sheetsViewport.style.marginTop=optMobileWebHeader.offsetHeight+
(optTopBar?optTopBar.offsetHeight:0)+'px';
}
varadjustedHeight=window.innerHeight-
(optTopBar?optTopBar.offsetHeight:0)-
(optFooter?optFooter.offsetHeight:0);
varadjustedWidth=window.innerWidth;
sheetsViewport.style.width=(adjustedWidth+'px');
sheetsViewport.style.height=(adjustedHeight+'px');
if(optPageSwitcher){
optPageSwitcher.resize(adjustedWidth,adjustedHeight);
}
}
resize();
window.onresize=resize;
varcurrentUrl=window.location.href;
varnewUrl=currentUrl.replace('?sle=true&','?');
newUrl=newUrl.replace('?sle=true','');
newUrl=newUrl.replace('&sle=true&','&');
newUrl=newUrl.replace('&sle=true','');
window.history.replaceState(null,'',newUrl);
}
<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">_docs_flag_initialData={"docs-mwid":false,"docs-smheo":false,"info_params":{"includes_info_params":true},"ilcm":{"eui":"ADFN-ctoHzWx9j47QMwHvC0oA13I7GJCkxvKJTCVQTTUU5ZYqxEV1bNi0EwGJn7mYxWxdHBMXlSK","je":1,"sstu":1623926851831000,"si":"CNSQlPm-nvECFVaGqwcd6RgGyw","gsc":0,"ei":[5707711,5703186,5731094,5708862,5705301,5714628,5707197,5728103,5737700,5700019,5713152,5723284,5717118,5704063,5711808,5710677,5709709,5737898,5733710,5714961,5715515,5709892,5707385,5708480,5709381,5707047,5715399,5715637,5719170,5706133,5714843,5716141,5738168,5703913,5723871,5712352,5702767,5707943,5702912,5710637,5711708,5711850,5720479,5737401,5720568,5725052,5722301,5712033,5704621,5704883,5700559,5721815,5719212,5707609,5710645,5717949,5713207,5711471,5739056,5701903,5724085,5702135,5708574,5721004,5708886,5733973,5706601,5733570,5737254,5713227,5728335,5732963,5725300,5725338,5720788,5713681,5705777,5714796,5712469,5716149,5700884,5714326,5724916,5709476,5711765,5713195,5728567,5716028,5704144,5720487,5735134,5715364,5707986,5720483,5710746,5706169,5711550,5712929,5720925,5711099,5721764,5704641,5711155,5720595,5728475,5702849,5719535,5713597,5714322,5720516,5717161,5713223,5707204,5705040,5701034,5707856,5711012,5703837,5730285,5713049,5712909,5735509,5714674,5702445,5714967,5734352,5713605,5710476,5711957,5720714,5703591,5727257,5724896,5708974,5706933,5710938,5724533,5703027,5729546,5712905,5711297,5722346,5712525,5710933,5713542,5728515,5707445,5710542,5715641,5702785,5712298,5708870,5719527,5714330,5735281,5728083,5711685,5722409,5715222,5727901,5731530,5719462,5709661,5727063,5721344,13702623,5706069,5710893,5712211,5731412,5712477,5703839,5711826,5717070,5713191,5730290,5727853,5716457,5702936,5705223,5706270,5731783,5711524,5713554,5707819,5703022,5703815,5703182,5719482,5712373,5711769,5725742,5737153,5734571,5705493,5720060,5700422,5721012,5719531,5714839,5726110,5705581,5712913,5709357,5735670,5722370,5719651,5711230,5704581,5728945,5711889,5715246,5725511,5727042,5712635,5707425,5706523,5721361,5719502,5700446,5728807,5722189,5719418,5706661,5734994,5722567,5714445,5710692,5736924,5714550,5713333,5701650,5726190,5703762,5721307,5726595,5714310,5707137,5712473,5715824,5709447,5730867,5705649,5716416,5703259,5738433,5735806,5709085,5713211,5701594,5723679,5729072,5706007,5706751,5729206,5716145,5713657,5707657,5735630,5723365,5727624],"crc":0,"cvi":[]},"drive_url":"//drive.google.com?usp\u003dsheets_web","docs-ehr":true,"docs-sup":"/spreadsheets"};_docs_flag_cek='';if(window['DOCS_timing']){DOCS_timing['ifdld']=newDate().getTime();}<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">document.addEventListener('DOMContentLoaded',init);<bodyclass="docs-gm"><divid="top-bar"><divid="doc-title"><spanclass="name">MYMNutraceuticals:KeyShareInfo2<divid="sheets-viewport"><divid="1294638516"style="display:none;position:relative;"dir="ltr"><divclass="ritzgrid-container"dir="ltr"><tableclass="waffle"cellspacing="0"cellpadding="0">
class="row-headerfreezebar-origin-ltrheader-shimrow-header-shim"><thid="1294638516C0"style="width:191px;"class="header-shim"><thid="1294638516C1"style="width:100px;"class="header-shim">
style="height:20px"><thid="1294638516R0"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">1<tdclass="s0">EnterpriseValue(inMIllions)class="s1">$14.24
style="height:20px"><thid="1294638516R1"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">2<tdclass="s0">TTMRevenueclass="s1">$1.78
style="height:20px"><thid="1294638516R2"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">3<tdclass="s0">TTMGrowthMargin%class="s1">65.27%
style="height:20px"><thid="1294638516R3"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">4<tdclass="s0">TTMOperatingExpensesclass="s1">$16.26
style="height:20px"><thid="1294638516R4"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">5<tdclass="s0">TTMOCFclass="s1">-$8.63
style="height:20px"><thid="1294638516R5"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">6<tdclass="s0">P/STTMclass="s1">8.47
style="height:20px"><thid="1294638516R6"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">7<tdclass="s0">P/S(LastQuarterRunRate)class="s1">#DIV/0!
<divid="footer">Publishedby<atarget="_blank"title="LearnmoreaboutGoogleSheets"href="https://docs.google.com/spreadsheets/?usp=sheets_web">GoogleSheets<spanclass="dash">–<ahref="https://docs.google.com/abuse?id=AKkXjoxJPPdT2XZQJ9j1xk56iAncfZHswcfOdDDCv4pDyGeDPRtPlG4JrPFvJQk1Nj2IigePBFtgXVU3uPjrW-o:0">ReportAbuse<spanclass="dash">–Updatedautomaticallyevery5minutes
<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">activeSheetId='1294638516';switchToSheet('1294638516');

Key Balance Sheet Information (in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.11$0.32$0.55$0.27$2.04$10.11$6.63$1.74$0.91$1.72
Biological Assets
Inventory$0.04$0.03$0.06$0.10$1.06$1.11$0.81$0.77
Total Assets$0.13$0.49$1.77$2.12$6.62$20.45$21.11$22.50$20.27$20.04
Net Tangible Assets$0.12$0.48$0.87$1.05$4.99$16.89$17.22$18.61$17.17$16.94
Intangibles/Goodwill$0.00$0.00$0.90$1.07$1.63$3.56$3.89$3.89$3.10$3.10
Total Liabilities$0.42$0.35$0.26$0.25$0.57$1.28$1.20$2.95$1.16$0.87

Key Operating Items (Quarterly in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.14$0.28$0.40$0.48$1.78
Change in Fair Value of Biologial Assets
Gross Margin$0.06$0.19$0.25$0.40$1.16
Marketing and Sales
Investor Relations$0.00$0.01$0.02$0.12$0.32$0.58$1.570.230.34$0.43
Total Operating Expenses$0.04$0.10$0.88$0.79$1.25$2.20$6.782.732.78$3.98
Operating Cash Flow (Quarterly)-$0.03-$0.21-$0.43-$1.09-$1.60-$3.75-4.08-$0.80
Investing Cash Flow (Quarterly)-$0.07$0.02-$1.70-$2.70-$1.88-1.61-$0.03
Financing Cash Flow (Quarterly)$0.00$0.48$0.64$4.56$12.36$2.154.87$1.64

Listing Statement

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres